AU2001233063A1 - Vaccination of hiv infected persons following highly active antiretroviral therapy - Google Patents
Vaccination of hiv infected persons following highly active antiretroviral therapyInfo
- Publication number
- AU2001233063A1 AU2001233063A1 AU2001233063A AU3306301A AU2001233063A1 AU 2001233063 A1 AU2001233063 A1 AU 2001233063A1 AU 2001233063 A AU2001233063 A AU 2001233063A AU 3306301 A AU3306301 A AU 3306301A AU 2001233063 A1 AU2001233063 A1 AU 2001233063A1
- Authority
- AU
- Australia
- Prior art keywords
- vaccination
- highly active
- hiv infected
- antiretroviral therapy
- infected persons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17927600P | 2000-01-31 | 2000-01-31 | |
US60/179,276 | 2000-01-31 | ||
PCT/US2001/002766 WO2001054701A1 (en) | 2000-01-31 | 2001-01-26 | Vaccination of hiv infected persons following highly active antiretroviral therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001233063A1 true AU2001233063A1 (en) | 2001-08-07 |
Family
ID=22655900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001233063A Abandoned AU2001233063A1 (en) | 2000-01-31 | 2001-01-26 | Vaccination of hiv infected persons following highly active antiretroviral therapy |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001233063A1 (en) |
WO (1) | WO2001054701A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
CN101076247A (en) * | 2003-09-18 | 2007-11-21 | 默克公司 | Therapeutic immunization of HIV-infected individuals |
EP2309269B1 (en) * | 2004-09-08 | 2016-10-26 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Compositions and methods for the detection of HIV-1/HIV-2 infection. |
EP2477651A1 (en) * | 2009-09-17 | 2012-07-25 | Sanofi Pasteur Inc. | Immunological compositions for hiv |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0942747A1 (en) * | 1996-08-26 | 1999-09-22 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
CA2380018A1 (en) * | 1999-07-28 | 2001-02-08 | The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services | Immunotherapy in hiv infected persons using vaccines after multi-drug treatment |
-
2001
- 2001-01-26 WO PCT/US2001/002766 patent/WO2001054701A1/en active Application Filing
- 2001-01-26 AU AU2001233063A patent/AU2001233063A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001054701A9 (en) | 2002-10-31 |
WO2001054701A1 (en) | 2001-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001261198A1 (en) | Patient point of care computer system | |
AU2001280440A1 (en) | Treatment of human herpesviruses using hyperthermia | |
ATE413188T1 (en) | HUMAN PAPILLOMAVIRUS VACCINE FORMULATIONS | |
AU1167602A (en) | Methods of therapy for hiv infection | |
IL150961A0 (en) | Human immunodeficiency virus vaccine | |
AU2001241918A1 (en) | Methods of enhancing activity of vaccines and vaccine compositions | |
AU2001265253A1 (en) | Treatment of hiv using hyperthermia | |
AU2001238501A1 (en) | Selective destruction of cells infected with human immunodeficiency virus | |
AU2002343321A8 (en) | Isolation and purification of p. falciparum merozoite protein-142 vaccine | |
AU2002219881A1 (en) | Methods and compositions for the treatment of human immunodeficiency virus infection | |
AU4088697A (en) | Postinfection human immunodeficiency virus (hiv) vaccination therapy | |
AU2002210407A1 (en) | Therapeutic vaccine formulations containing chitosan | |
AU2001233063A1 (en) | Vaccination of hiv infected persons following highly active antiretroviral therapy | |
AU2003210659A1 (en) | Combination therapy for treatment of hiv infection | |
AU2281601A (en) | Treatment of viral infections using levovirinTM | |
AU2002220257A1 (en) | Methods of treatment involving human mda-7 | |
AU2002343146A1 (en) | Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections | |
AU2001258785A1 (en) | Sterilization of silicone preparations | |
AU2001265280A1 (en) | Preparation of 2-hydroxy-5-oxoproline and analogs thereof | |
AU2002364163A1 (en) | USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY | |
AU2002252610A1 (en) | Ultrasonic profiling of medicament administration into tissue | |
AU2960000A (en) | Detection of human immunodeficiency virus | |
AU2002360523A1 (en) | Compounds to treat hiv infection and aids | |
AU2002322424A1 (en) | Novel methods and formulations for administration of active agents | |
AU2002332613A1 (en) | Compositions and therapeutic methods for viral infection |